Liminal BioSciences announces 10-for-1 reverse stock split

Liminal BioSciences announced that a consolidation of all of the issued and outstanding common shares of the company on the basis of a consolidation ratio of ten pre-consolidation common shares for one post-consolidation common share will become effective at the opening of trading on February 1. The company’s current trading symbol will remain unchanged. The consolidation was previously approved by the company’s shareholders at the special meeting of the shareholders held on January 20.